Search

Wearable temperature sensors with high accuracy are critical for human health monitoring. Ideally, they should show accuracy matching that of medical‐grade thermometers (i.e., ± ≈0.1–0.2 °C). Achieving this goal has proven challenging for sensors that must also meet key wearable requirements, such as flexibility, stretchability, and breathability. Herein, a new stretchable supercapacitive temperature sensor with a resolution of ±0.2 °C, is presented, which was achieved by. Two new strategies to increase temperature sensitivity and minimize the interferences of mechanical stretching and pressure: a) synthesizing an ion‐conductive NaCl‐organogel to serve as the redox‐active separator to increase sensitivity and suppress interference of compression; and b) using a kirigami design to decrease the interference of stretch and improve breathability. These two novel strategies endow the supercapacitive temperature sensors with a temperature accuracy of ±0.2 °C and exceptionally high sensitivity of 0.095 °C−1, which is more than 13 times higher than traditional dielectric‐capacitive sensors. The potential of the supercapacitive sensor in measuring body temperature is demonstrated by continuously monitoring skin temperatures under a medical compression garment that exerts pressure on the skin and the unsteady wrist flexion. The findings confirm that the organogel‐based supercapacitive sensors offer an extraordinary temperature accuracy significantly better than wearable sensors reported in the literature. The combined characteristics of high resolution, linearity, breathability, and stretchability make this sensor a promising candidate for skin‐interfaced health monitoring devices. [ABSTRACT FROM AUTHOR]

Objectives: To investigate whether serial prostate magnetic resonance imaging (MRI) may guide the utility of repeat targeted (TBx) and systematic biopsy (SBx) when monitoring men with low‐risk prostate cancer (PCa) at 1‐year of active surveillance (AS). Patients and Methods: We retrospectively included 111 consecutive men with low‐risk (International Society of Urological Pathology [ISUP] Grade 1) PCa, who received protocolled repeat MRI with or without TBx and repeat SBx at 1‐year of AS. TBx was performed in Prostate Imaging‐Reporting and Data System (PI‐RADS) score ≥3 lesions (MRI‐positive men). Upgrading defined as ISUP Grade ≥2 PCa (I), Grade ≥2 with cribriform growth/intraductal carcinoma PCa (II), and Grade ≥3 PCa (III) was investigated. Upgrading detected by TBx only (not by SBx) and SBx only (not by TBx) was investigated in MRI‐positive and ‐negative men, and related to radiological progression on MRI (Prostate Cancer Radiological Estimation of Change in Sequential Evaluation [PRECISE] score). Results: Overall upgrading (I) was 32% (35/111). Upgrading in MRI‐positive and ‐negative men was 48% (30/63) and 10% (5/48) (P < 0.001), respectively. In MRI‐positive men, there was upgrading in 23% (seven of 30) by TBx only and in 33% (10/30) by SBx only. Radiological progression (PRECISE score 4–5) in MRI‐positive men was seen in 27% (17/63). Upgrading (I) occurred in 41% (seven of 17) of these MRI‐positive men, while this was 50% (23/46) in MRI‐positive men without radiological progression (PRECISE score 1–3) (P = 0.534). Overall upgrading (II) was 15% (17/111). Upgrading in MRI‐positive and ‐negative men was 22% (14/63) and 6% (three of 48) (P = 0.021), respectively. In MRI‐positive men, there was upgrading in three of 14 by TBx only and in seven of 14 by SBx only. Overall upgrading (III) occurred in 5% (five of 111). Upgrading in MRI‐positive and ‐negative men was 6% (four of 63) and 2% (one of 48) (P = 0.283), respectively. In MRI‐positive men, there was upgrading in one of four by TBx only and in two of four by SBx only. Conclusion: Upgrading is significantly lower in MRI‐negative compared to MRI‐positive men with low‐risk PCa at 1‐year of AS. In serial MRI‐negative men, the added value of repeat SBx at 1‐year surveillance is limited and should be balanced individually against the harms. In serial MRI‐positive men, the added value of repeat SBx is substantial. Based on this cohort, SBx is recommended to be performed in combination with TBx in all MRI‐positive men at 1‐year of AS, also when there is no radiological progression. [ABSTRACT FROM AUTHOR]